Clinical trials for Prostate cancer

147 currently recruiting clinical trials
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Neuroendocrine carcinoma MSI/dMMR None Systemic Treatment-Naive
Immunotherapy Radiotherapy
6 recruiting sites
UNICANCER
Phase 2 Prostate cancer #NCT07287150 #2025-521327-67-00
Adenocarcinoma Metastatic Castration-resistant 1 Hormone therapy Hormone therapy
Chemotherapy
2 recruiting sites
Hoffmann-La Roche
Phase 2 Prostate cancer #NCT07016230 #2024-515847-47-00
Neuroendocrine carcinoma Metastatic Hormone-sensitive Metastatic Castration-resistant 1 2 3 or more Chemotherapy
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Prostate cancer #NCT06866938 #2024-512043-22-00
Adenocarcinoma Metastatic Castration-resistant PSMA PET Positive Chemotherapy Hormone therapy
Systemic Treatment-Naive
5 recruiting sites
Hospices Civils de Lyon
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Locally Advanced Metastatic Metastatic Castration-resistant EGFR FGFR MET 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2 Prostate cancer #NCT06172478 #2023-507641-29-00
Cancer de la prostate résistant à la castration
Adenocarcinoma Metastatic Castration-resistant 1 2 3 or more Chemotherapy Hormone therapy
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Prostate cancer #NCT07005154 #2024-517653-27-00
Adenocarcinoma Metastatic Hormone-sensitive None Systemic Treatment-Naive
2 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 2 Prostate cancer #NCT07005154 #2024-517653-27-00
Adenocarcinoma Metastatic Castration-resistant None 1 Hormone therapy
Systemic Treatment-Naive
2 recruiting sites
Astellas Pharma Développement mondial, Inc.